Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S.

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...

Yue Guan of Wanhuida Intellectual Property considers the CNIPA’s evidentiary standards after its invalidation of a patent for ...

Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pär Gellerfors, as well as the company's CEO, Gunilla Osswald, have been ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Eisai Co (ESALF – Research Report), with a price ...

Layoffs are a fact of life in the pharma and biotech industries with companies frequently adjusting headcount as their priorities shift. But the steady stream of cuts grew stronger last year as ...

Newron to participate in a fireside chat at the 37th Annual ROTH Conference on Monday, March 17 at 11:30 am PDT.

For baby boomers, ultra-safe dividend stocks like these five that can add passive income streams to Social Security benefits.